{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T11:15:46Z","timestamp":1793013346618,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.antiviral.2022.105271","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T02:08:50Z","timestamp":1646014130000},"page":"105271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concern"],"prefix":"10.1016","volume":"199","author":[{"given":"Tsung-I","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jahan S.","family":"Khalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gilchrist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B.","family":"Waight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniella","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muran","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda Nga-Sze","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2949-2454","authenticated-orcid":false,"given":"Dennis R.","family":"Goulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"36","key":"10.1016\/j.antiviral.2022.105271_bib2","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2103154118","article-title":"SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma","volume":"118","author":"Andreano","year":"2021","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.antiviral.2022.105271_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.27588","article-title":"Omicron variant of SARS\u2010CoV\u20102: genomics, transmissibility, and responses to current COVID\u201019 vaccines","author":"Araf","year":"2022","journal-title":"J. Med. Virol."},{"issue":"3","key":"10.1016\/j.antiviral.2022.105271_bib4","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4103\/0975-1483.66810","article-title":"TGN1412: from discovery to disaster","volume":"2","author":"Attarwala","year":"2010","journal-title":"J. Young Pharm."},{"issue":"15","key":"10.1016\/j.antiviral.2022.105271_bib5","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 vaccine booster against covid-19 in Israel","volume":"385","author":"Bar-On","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"8 August","key":"10.1016\/j.antiviral.2022.105271_bib6","article-title":"Development and simulation of fully glycosylated molecular models of ace2-fc fusion proteins and their interaction with the sars-cov-2 spike protein binding domain","volume":"15","author":"Bernardi","year":"2020","journal-title":"PLoS One"},{"issue":"D1","key":"10.1016\/j.antiviral.2022.105271_bib7","doi-asserted-by":"crossref","first-page":"D1195","DOI":"10.1093\/nar\/gky994","article-title":"Glycosciences.DB: an annotated data collection linking glycomics and proteomics data (2018 update)","volume":"47","author":"B\u00f6hm","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"7887","key":"10.1016\/j.antiviral.2022.105271_bib8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/d41586-021-03552-w","article-title":"Heavily mutated Omicron variant puts scientists on alert","volume":"600","author":"Callaway","year":"2021","journal-title":"Nature"},{"issue":"1 SE-Debate","key":"10.1016\/j.antiviral.2022.105271_bib9","first-page":"157","article-title":"WHO declares COVID-19 a pandemic","volume":"91","author":"Cucinotta","year":"2020","journal-title":"Acta. Biomed. Atenei. Parm."},{"issue":"6","key":"10.1016\/j.antiviral.2022.105271_bib10","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/infdis\/jiab368","article-title":"SARS-CoV-2 B.1.617 mutations L452R and E484Q are not synergistic for antibody evasion","volume":"224","author":"Ferreira","year":"2021","journal-title":"J. Infect. Dis."},{"issue":"34","key":"10.1016\/j.antiviral.2022.105271_bib11","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.15585\/mmwr.mm7034e4","article-title":"Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B.1.617.2 (delta) variant predominance \u2014 eight U.S. Locations, december 2020\u2013august 2021","volume":"70","author":"Fowlkes","year":"2021","journal-title":"Morb. Mortal. Wkly. Rep."},{"issue":"3","key":"10.1016\/j.antiviral.2022.105271_bib12","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cell.2021.12.033","article-title":"mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant","volume":"185","author":"Garcia-Beltran","year":"2022","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.antiviral.2022.105271_bib13","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","article-title":"Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system","volume":"126","author":"Gheblawi","year":"2020","journal-title":"Circ. Res."},{"issue":"45","key":"10.1016\/j.antiviral.2022.105271_bib14","doi-asserted-by":"crossref","first-page":"28046","DOI":"10.1073\/pnas.2016093117","article-title":"Engineered ACE2 receptor traps potently neutralize SARS-CoV-2","volume":"117","author":"Glasgow","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.antiviral.2022.105271_bib15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.antiviral.2022.105271_bib16","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012828","article-title":"Humanized COVID\u201019 decoy antibody effectively blocks viral entry and prevents SARS\u2010CoV\u20102 infection","volume":"13","author":"Huang","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.antiviral.2022.105271_bib17","article-title":"Novel ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV2","volume":"2020","author":"Iwanaga","year":"2020","journal-title":"bioRxiv"},{"issue":"578825","key":"10.1016\/j.antiviral.2022.105271_bib18","article-title":"The mechanisms and animal models of SARS-CoV-2 infection","volume":"9","author":"Jia","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"1744","key":"10.1016\/j.antiviral.2022.105271_bib19","article-title":"SARS-CoV-2 spike pseudoviruses: a useful tool to study virus entry and address emerging neutralization escape phenotypes","volume":"9","author":"Kalkeri","year":"2021","journal-title":"Microorganisms"},{"issue":"10","key":"10.1016\/j.antiviral.2022.105271_bib20","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","article-title":"Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies","volume":"5","author":"Lee","year":"2020","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.antiviral.2022.105271_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102452","article-title":"Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?","volume":"111","author":"Liu","year":"2020","journal-title":"J. Autoimmun."},{"issue":"9","key":"10.1016\/j.antiviral.2022.105271_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ijcp.14462","article-title":"Changes of serum IL-10, IL-1\u03b2, IL-6, MCP-1, TNF-\u03b1, IP-10 and IL-4 in COVID-19 patients","volume":"75","author":"Lu","year":"2021","journal-title":"Int. J. Clin. Pract."},{"issue":"5","key":"10.1016\/j.antiviral.2022.105271_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01987-21","article-title":"Antibody-dependent enhancement of SARS-CoV-2 infection is mediated by the IgG receptors Fc\u03b3RIIA and Fc\u03b3RIIIA but does not contribute to aberrant cytokine production by macrophages","volume":"12","author":"Maemura","year":"2021","journal-title":"mBio"},{"issue":"6534","key":"10.1016\/j.antiviral.2022.105271_bib24","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1126\/science.abf6950","article-title":"Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape","volume":"371","author":"McCarthy","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2022.105271_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-021-03944-y","article-title":"SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion","author":"Mlcochova","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2022.105271_bib26","article-title":"Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study","volume":"10","author":"Naaber","year":"2021","journal-title":"Lancet Reg Heal - Eur."},{"issue":"4","key":"10.1016\/j.antiviral.2022.105271_bib27","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41591-021-01283-z","article-title":"Post-acute COVID-19 syndrome","volume":"27","author":"Nalbandian","year":"2021","journal-title":"Nat. Med."},{"issue":"34","key":"10.1016\/j.antiviral.2022.105271_bib28","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.15585\/mmwr.mm7034e3","article-title":"Effectiveness of pfizer-BioNTech and moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (delta) variant \u2014 national healthcare safety network, March 1\u2013august","volume":"70","author":"Nanduri","year":"2021","journal-title":"Morb. Mortal. Wkly. Rep."},{"issue":"4","key":"10.1016\/j.antiviral.2022.105271_bib29","doi-asserted-by":"crossref","first-page":"928","DOI":"10.4161\/mabs.28744","article-title":"Characterization and screening of IgG binding to the neonatal Fc receptor","volume":"6","author":"Neuber","year":"2014","journal-title":"mAbs"},{"issue":"2","key":"10.1016\/j.antiviral.2022.105271_bib30","first-page":"1","article-title":"Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool","volume":"7","author":"O'Toole","year":"2021","journal-title":"Virus Evol"},{"issue":"12","key":"10.1016\/j.antiviral.2022.105271_bib31","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1038\/nm1143","article-title":"Severe acute respiratory syndrome","volume":"10","author":"Peiris","year":"2004","journal-title":"Nat. Med."},{"issue":"13","key":"10.1016\/j.antiviral.2022.105271_bib32","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera\u2014a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.antiviral.2022.105271_bib33","article-title":"Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of alpha and delta variant prevalence","author":"Puranik","year":"2021","journal-title":"medRxiv"},{"issue":"2","key":"10.1016\/j.antiviral.2022.105271_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.00789-21","article-title":"The emergence of sars-CoV-2 variant lambda (C.37) in south America","volume":"9","author":"Romero","year":"2021","journal-title":"Microbiol. Spectr."},{"issue":"10273","key":"10.1016\/j.antiviral.2022.105271_bib35","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(21)00183-5","article-title":"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence","volume":"397","author":"Sabino","year":"2021","journal-title":"Lancet"},{"issue":"5532","key":"10.1016\/j.antiviral.2022.105271_bib36","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1126\/science.1061692","article-title":"Crystal structure of a neutralizing human IgG against HIV-1: a template for vaccine design","volume":"293","author":"Saphire","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2022.105271_bib37","author":"Schr\u00f6dinger"},{"issue":"35","key":"10.1016\/j.antiviral.2022.105271_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/1560-7917.ES.2021.26.35.2100793","article-title":"Vaccine effectiveness against infection with the delta (B.1.617.2) variant, Norway, april to August 2021","volume":"26","author":"Sepp\u00e4l\u00e4","year":"2021","journal-title":"Euro Surveill."},{"issue":"4","key":"10.1016\/j.antiviral.2022.105271_bib39","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s12276-021-00604-z","article-title":"On the origin and evolution of SARS-CoV-2","volume":"53","author":"Singh","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.antiviral.2022.105271_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fpls.2020.604663","article-title":"Development of plant-produced recombinant ACE2-fc fusion protein as a potential therapeutic agent against SARS-CoV-2","volume":"11","author":"Siriwattananon","year":"2021","journal-title":"Front. Plant Sci."},{"key":"10.1016\/j.antiviral.2022.105271_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105197","article-title":"Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein","volume":"196","author":"Svilenov","year":"2021","journal-title":"Antivir. Res."},{"issue":"6","key":"10.1016\/j.antiviral.2022.105271_bib42","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/rmv.405","article-title":"Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications","volume":"13","author":"Takada","year":"2003","journal-title":"Rev. Med. Virol."},{"issue":"4","key":"10.1016\/j.antiviral.2022.105271_bib43","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.jinf.2020.12.024","article-title":"Emergence of a new SARS-CoV-2 variant in the UK","volume":"82","author":"Tang","year":"2021","journal-title":"J. Infect."},{"issue":"7854","key":"10.1016\/j.antiviral.2022.105271_bib44","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","article-title":"Detection of a SARS-CoV-2 variant of concern in South Africa","volume":"592","author":"Tegally","year":"2021","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.antiviral.2022.105271_bib45","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.micinf.2020.02.006","article-title":"Is COVID-19 receiving ADE from other coronaviruses?","volume":"22","author":"Tetro","year":"2020","journal-title":"Microb. Infect."},{"issue":"19","key":"10.1016\/j.antiviral.2022.105271_bib46","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.antiviral.2022.105271_bib47","doi-asserted-by":"crossref","first-page":"17996","DOI":"10.1074\/jbc.M311191200","article-title":"ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis *","volume":"279","author":"Towler","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"21","key":"10.1016\/j.antiviral.2022.105271_bib48","first-page":"1","article-title":"Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study","volume":"3099","author":"Twohig","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"6557","key":"10.1016\/j.antiviral.2022.105271_bib49","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1126\/science.373.6557.838","article-title":"Israel's grim warning: delta can overwhelm shots","volume":"373","author":"Wadman","year":"2021","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.antiviral.2022.105271_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/JVI.02015-19","article-title":"Molecular mechanism for antibody-dependent enhancement of coronavirus entry","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105271_bib51","series-title":"Marsh M, van der Meer JWM, Montefiore D, eds. Elife.","article-title":"Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants","volume":"vol. 9","author":"Weisblum","year":"2020"},{"key":"10.1016\/j.antiviral.2022.105271_bib1","year":"2020"},{"key":"10.1016\/j.antiviral.2022.105271_bib52","series-title":"Ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2016"},{"issue":"2","key":"10.1016\/j.antiviral.2022.105271_bib53","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41594-020-00549-3","article-title":"A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent","volume":"28","author":"Xiao","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"May","key":"10.1016\/j.antiviral.2022.105271_bib54","article-title":"COVID-19 pandemic dynamics in India and impact of the SARS-CoV-2 Delta (B.1.617.2) variant","author":"Yang","year":"2021","journal-title":"medRxiv"},{"issue":"19","key":"10.1016\/j.antiviral.2022.105271_bib55","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"65","key":"10.1016\/j.antiviral.2022.105271_bib56","article-title":"Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo","volume":"7","author":"Zhang","year":"2021","journal-title":"Cell Discov"},{"issue":"7798","key":"10.1016\/j.antiviral.2022.105271_bib57","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.antiviral.2022.105271_bib58","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S2213-2600(20)30418-5","article-title":"Human recombinant soluble ACE2 in severe COVID-19","volume":"8","author":"Zoufaly","year":"2020","journal-title":"Lancet Respir. Med."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354222000390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354222000390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:35:05Z","timestamp":1759062905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354222000390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":58,"alternative-id":["S0166354222000390"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2022.105271","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concern","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2022.105271","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105271"}}